CL2018001868A1 - Análogos del egf(a) con sustituyentes de ácidos grasos. - Google Patents

Análogos del egf(a) con sustituyentes de ácidos grasos.

Info

Publication number
CL2018001868A1
CL2018001868A1 CL2018001868A CL2018001868A CL2018001868A1 CL 2018001868 A1 CL2018001868 A1 CL 2018001868A1 CL 2018001868 A CL2018001868 A CL 2018001868A CL 2018001868 A CL2018001868 A CL 2018001868A CL 2018001868 A1 CL2018001868 A1 CL 2018001868A1
Authority
CL
Chile
Prior art keywords
egf
fatty acid
analogues
compounds
acid substituents
Prior art date
Application number
CL2018001868A
Other languages
English (en)
Inventor
Jianhe Chen
Jesper F Lau
János Tibor Kodra
Birgit Wieczorek
Lars Linderoth
Henning Thøgersen
Salka Elbøl Rasmussen
Patrick William Garibay
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CL2018001868A1 publication Critical patent/CL2018001868A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCIÓN SE REFIERE A COMPUESTOS DERIVADOS DEL DOMINIO EGF(A) DE LDL-R, EN PARTICULAR A COMPUESTOS QUE COMPRENDEN UN ANÁLOGO PEPTÍDICO DE LA SECUENCIA DE EGF(A) SILVESTRE (LDL-R(293-332)) Y AL MENOS UN SUSTITUYENTE QUE COMPRENDE AL MENOS UN GRUPO DE ÁCIDO GRASO. LA INVENCIÓN SE REFIERE, ADEMÁS, A UNA COMPOSICIÓN FARMACÉUTICA DE ESTOS Y SU USO COMO MEDICAMENTO. LOS NOVEDOSOS COMPUESTOS DE EGF(A) DE LA INVENCIÓN SON ÚTILES COMO TRATAMIENTO, POR EJEMPLO, EN EL CAMPO DE LA DISMINUCIÓN DE COLESTEROL, DISLIPIDEMIA Y ENFERMEDAD CARDIOVASCULAR.
CL2018001868A 2016-01-13 2018-07-09 Análogos del egf(a) con sustituyentes de ácidos grasos. CL2018001868A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016070791 2016-01-13
CN2016076580 2016-03-17
EP16195965 2016-10-27

Publications (1)

Publication Number Publication Date
CL2018001868A1 true CL2018001868A1 (es) 2018-08-31

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001868A CL2018001868A1 (es) 2016-01-13 2018-07-09 Análogos del egf(a) con sustituyentes de ácidos grasos.

Country Status (26)

Country Link
US (2) US10822385B2 (es)
EP (1) EP3402811B1 (es)
JP (2) JP6797926B2 (es)
KR (1) KR102417487B1 (es)
CN (1) CN108473550B (es)
AU (1) AU2017207862B2 (es)
BR (1) BR112018013820A2 (es)
CA (1) CA3010756A1 (es)
CL (1) CL2018001868A1 (es)
CO (1) CO2018007440A2 (es)
DK (1) DK3402811T3 (es)
ES (1) ES2916998T3 (es)
HR (1) HRP20220720T1 (es)
HU (1) HUE058647T2 (es)
IL (1) IL260043A (es)
LT (1) LT3402811T (es)
MX (1) MX2018008681A (es)
MY (1) MY195199A (es)
PE (1) PE20181376A1 (es)
PH (1) PH12018501502A1 (es)
PL (1) PL3402811T3 (es)
RS (1) RS63298B1 (es)
RU (1) RU2747877C2 (es)
SA (1) SA518391996B1 (es)
SI (1) SI3402811T1 (es)
WO (1) WO2017121850A1 (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793556B2 (en) 2016-01-13 2020-10-06 Gruenenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807989B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807988B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10829480B2 (en) 2016-01-13 2020-11-10 Gruenenthal Gmbh 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018008681A (es) 2016-01-13 2018-09-17 Novo Nordisk As Analogos del dominio a similar al factor de crecimiento epidermico (egf(a)) con sustituyentes de acidos grasos.
US20200165313A1 (en) * 2017-07-19 2020-05-28 Novo Nordisk A/S Egf(a) analogues, preparation, formulations and uses thereof
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
US11358994B2 (en) * 2017-07-27 2022-06-14 Saint Louis University Fatty acid modified human epidermal growth factor
AR116605A1 (es) 2018-10-05 2021-05-26 Novo Nordisk As Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
US11633632B2 (en) 2019-03-22 2023-04-25 3M Innovative Properties Company Fall-protection system with monitoring system
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
MX2022000889A (es) 2019-08-07 2022-02-14 Novo Nordisk As Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MX2022004718A (es) 2019-11-07 2022-06-08 Novo Nordisk As Omposiciones sólidas que comprenden un inhibidor de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616551A1 (en) 2005-07-29 2007-02-15 Amprotein Corporation Chimeric therapeutic agents
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
US8962794B2 (en) 2007-08-15 2015-02-24 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
AU2009238550B2 (en) * 2008-04-23 2014-11-27 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 ( PCSK9) variants and uses thereof
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
US8939592B2 (en) * 2010-08-02 2015-01-27 Nec Corporation Polarizer and light-emitting device
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
EP2675470A1 (en) 2011-02-15 2013-12-25 Novo Nordisk A/S Long-acting il-1 receptor antagonists
CN103717615A (zh) 2011-06-20 2014-04-09 霍夫曼-拉罗奇有限公司 结合pcsk9的多肽及使用方法
AU2012311484B2 (en) * 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
JP2015502971A (ja) * 2011-12-21 2015-01-29 ノヴォ ノルディスク アー／エス Ｎ末端修飾インスリン誘導体
CN112142855A (zh) 2012-05-18 2020-12-29 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
TW201420606A (zh) 2012-08-22 2014-06-01 Lilly Co Eli 同源二聚體蛋白
SG11201500682WA (en) 2012-09-07 2015-02-27 Sanofi Sa Fusion proteins for treating a metabolic syndrome
RS59124B1 (sr) * 2013-04-18 2019-09-30 Novo Nordisk As Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US10077319B2 (en) 2014-02-21 2018-09-18 Medimmune, Llc Anti-PCSK9-GLP-1 fusions and methods for use
EP3151852A1 (en) * 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CA2979617C (en) * 2015-03-19 2024-01-02 Institut De Cardiologie De Montreal Grp94 derived polypeptides for inhibiting pcsk9 and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
MX2018008681A (es) 2016-01-13 2018-09-17 Novo Nordisk As Analogos del dominio a similar al factor de crecimiento epidermico (egf(a)) con sustituyentes de acidos grasos.
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
US20200165313A1 (en) 2017-07-19 2020-05-28 Novo Nordisk A/S Egf(a) analogues, preparation, formulations and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793556B2 (en) 2016-01-13 2020-10-06 Gruenenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807989B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807988B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10829480B2 (en) 2016-01-13 2020-11-10 Gruenenthal Gmbh 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives

Also Published As

Publication number Publication date
JP2021035989A (ja) 2021-03-04
AU2017207862B2 (en) 2020-12-17
KR20180100177A (ko) 2018-09-07
RU2747877C2 (ru) 2021-05-17
SA518391996B1 (ar) 2021-07-14
DK3402811T3 (da) 2022-06-13
CN108473550A (zh) 2018-08-31
EP3402811B1 (en) 2022-03-30
US10822385B2 (en) 2020-11-03
KR102417487B1 (ko) 2022-07-06
PH12018501502A1 (en) 2019-03-25
CO2018007440A2 (es) 2018-09-28
US20190016768A1 (en) 2019-01-17
HRP20220720T1 (hr) 2022-09-30
LT3402811T (lt) 2022-06-10
HUE058647T2 (hu) 2022-09-28
ES2916998T3 (es) 2022-07-06
BR112018013820A2 (pt) 2018-12-11
MY195199A (en) 2023-01-11
RS63298B1 (sr) 2022-07-29
RU2018127882A (ru) 2020-02-13
PL3402811T3 (pl) 2022-07-11
JP6797926B2 (ja) 2020-12-09
WO2017121850A1 (en) 2017-07-20
EP3402811A1 (en) 2018-11-21
AU2017207862A1 (en) 2018-07-05
CN108473550B (zh) 2022-11-22
CA3010756A1 (en) 2017-07-20
SI3402811T1 (sl) 2022-06-30
RU2018127882A3 (es) 2020-06-19
IL260043A (en) 2018-07-31
JP2019505521A (ja) 2019-02-28
PE20181376A1 (es) 2018-09-05
US20200407409A1 (en) 2020-12-31
MX2018008681A (es) 2018-09-17

Similar Documents

Publication Publication Date Title
CL2018001868A1 (es) Análogos del egf(a) con sustituyentes de ácidos grasos.
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CO2017012832A2 (es) Compuestos derivados de d-fenilalanina - n - sustituidos con bicíclicos aromáticos, método de preparación de los mismos y composiciones farmacéuticas que los contienen
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
DOP2019000122A (es) Inhibidores de magl
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
DOP2019000121A (es) Inhibidores de magl
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
EA201890592A1 (ru) Жидкие фармацевтические композиции, содержащие ингибиторы sglt-2
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
BR112017010177A2 (pt) composição para tratamento de tecido
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
EA201790896A1 (ru) Пролекарства фенольных агонистов trpv1
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico
CL2020001687A1 (es) Nuevos compuestos inhibidores del blanco mecanístico de rapamicina (mtor).
EA201990560A1 (ru) Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии
CL2016000148A1 (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
ECSP15009391A (es) siARN Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES DE LOS OJOS
CL2020001686A1 (es) Compuestos inhibidores del blanco mecanístico de rapamicina (mtor).